Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Next Previous
Trial Profile

A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lazertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen Research & Development

Most Recent Events

  • 06 Jun 2023 Results from NCT02609776, NCT04077463, and NCT04075396; examining the incidence of VTE, a common adverse event among patients with lung cancer , presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 31 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 01 Jan 2023 Results assessing Effects of food and race on the pharmacokinetics of lazertinib (from 3 studies NCT03556436: Healthy subjects N = 24; NCT03046992 n=30 Asian subjects and NCT04075396, n=22 non Asian patients NSCLC patients ) in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer published in the Lung Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top